PROCEPT BioRobotics (PRCT), a medical robotics company, is now confronting a securities fraud class action lawsuit. The legal action is brought on behalf of investors who purchased the company's shares between February 28, 2024, and February 25, 2026.

The lawsuit alleges that the company and certain of its senior executives made false and misleading statements regarding the firm's business operations and financial outlook during this specific timeframe. According to the complaint, PROCEPT BioRobotics secretly employed a large-scale discount program during the class period to encourage customers to place bulk orders.

This practice artificially pulled forward future revenue, falsely inflating the company's reported handpiece sales and revenue figures. The scheme led to a situation where customer order volumes significantly exceeded actual surgical demand, a gap that reportedly widened over time.

The alleged plan was gradually revealed over three separate earnings disclosures. In August 2025, the company released its second-quarter results and lowered its shipment guidance for the following quarter, causing its stock price to fall roughly 16% over two days.

In November 2025, the company's third-quarter sales figures again fell short of guidance. It also reduced its full-year sales forecast while acknowledging that some customers might be "holding excess inventory," which triggered a stock price decline of more than 10%.

On February 25, 2026, the company disclosed that since the first quarter of 2023, handpiece sales had exceeded actual surgical volumes every quarter, resulting in a market surplus of over 10,000 units of excess inventory. Simultaneously, the company cancelled the long-standing discount program. Following this news, the stock price plummeted more than 18% over two trading days.

Several prominent law firms have now initiated class action lawsuits or launched investigations into the matter. Investors have until September 22, 2026, to file a motion with the court to serve as lead plaintiff.